Metalloproteinases in development and progression of vascular disease

Pathophysiology of Haemostasis and Thrombosis

Volumn 33, Issue 5-6, 2003, Pages 275-281

  Lijnen, H Roger ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Aneurysm; Atherosclerosis; Metalloproteinase; Neointima; Restenosis

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; AVASIMIBE; BATIMASTAT; DOXYCYCLINE; ILOMASTAT; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PLASMIN; PLASMINOGEN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

AMINO TERMINAL SEQUENCE; ANEURYSM; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR DISEASE; CAROTID ARTERY DISEASE; CELL MIGRATION; CONFERENCE PAPER; DISEASE COURSE; DNA POLYMORPHISM; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FIBRINOLYSIS; HUMAN; INTIMA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; RESTENOSIS; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

ANEURYSM; ANIMALS; ARTERIOSCLEROSIS; HUMANS; METALLOPROTEASES;

EID: 14044259261     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083814     Document Type: Conference Paper

References (83)

1. Herity NA, Ward MR, Lo S, Yeung AC: Review: Clinical aspects of vascular remodeling. J Cardiovasc Electrophysiol 1999; 10: 1016-1024.
2. Lijnen HR: Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 2001; 86: 324-333.
3. Galis ZS, Khatri JJ: Matrix metalloproteinases in vascular remodeling and atherogenesis. The good, the bad and the ugly. Circ Res 2002; 90: 251-262.
4. Dickey RP, Hover JF: Ultrasonographic features of uterine blood flow during the first 16 weeks of pregnancy. Hum Reprod 1995; 10: 2448-2452.
5. Visse R, Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases. Structure, function and biochemistry. Circ Res 2003; 92: 827-839.
6. Somerville RPT, Oblander SA, Apte SS: Matrix metalloproteinases: old dogs with new tricks. Genome Biology 2003; 4: 216.
7. Bode W, Gomis-Ruth FX, Stockler W: Astacins, serralysins, snake venom and matrix metalloproteinases exhibit identical zinc-binding environments (HEXXHXXGXXH and Met-turn) and topologies and should be grouped into a common family, the 'metzincins'. FEBS Lett 1993; 331: 134-140.
8. Massova I, Kotra LP, Fridman R, Mobashery S: Matrix metalloproteinases: structures, evolution, and diversification. FASEB J 1998; 12: 1075-1095.
9. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI: Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995; 270: 5331-5338.
10. Sato H, Seiki M: Membrane-type matrix metalloproteinases (MT-MMPs) in tumor metastasis. J Biochem (Tokyo) 1996; 119: 209-215.
11. Nagase H: Activation mechanisms of matrix metalloproteinases. Biol Chem 1997; 378: 151-160.
12. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000; 1477: 267-283.
13. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ: Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 2001; 89: 201-210.
14. Sierevogel MJ, Pasterkamp G, de Kleijn DP, Strauss BH: Matrix metalloproteinases: a therapeutic target in cardiovascular disease. Curr Pharm Des 2003; 9: 1033-1040.
15. Kuzuya M, Iguchi A: Role of matrix metalloproteinases in vascular remodeling. J Atheroscler Thromb 2003; 10: 275-282.
16. Jones CB, Sane DC, Herrington DM: Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res 2003; 59: 812-823.
17. Ikeda U, Shimada K: Matrix metalloproteinases and coronary artery diseases. Clin Cardiol 2003; 26: 55-59.
18. Irizarry E, Newman KM, Gandhi RH, Nackman GB, Halpern V, Wishner S, Scholes JV, Tilson MD: Demonstration of interstitial collagenase in abdominal aortic aneurysm disease. J Surg Res 1993; 54: 571-574.
19. Newman KM, Jean Claude J, Li H, Scholes JV, Ogata Y, Nagase H, Tilson MD: Cellular localization of matrix metalloproteinase in the abdominal aortic aneurysm wall. J Vasc Surg 1994; 20: 814-820.
20. Galis ZS, Sukhova GK, Kranzhöfer R, Clark S, Libby P: Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci USA 1995; 92: 402-406.
21. Halpert I, Sires UI, Roby JD, Potter-Perigo S, Wight TN, Shapiro SD, Welgus, HG, Wickline SA, Parks WC: Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci USA 1996; 93: 9748-9753.
22. Sakalihasan N, Delvenne P, Nusgens BV, Limet R, Lapiere CM: Activated forms of MMP2 and MMP9 in abdominal aortic aneurysms. J Vasc Surg 1996; 24: 127-133.
23. Moons L, Shi V, Ploplis V, Plow E, Haber E, Collen D, Carmeliet P: Reduced transplant arteriosclerosis in plasminogen deficient mice. J Clin Invest 1998; 102: 1788-1797.
24. Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA: Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res 1994; 75: 539-545.
25. Zempo N, Kenagy RD, Au YPT, Bendeck M, Clowes MM, Reidy MA, Clowes AW: Matrix metalloproteinases of vascular cells are increased in balloon-injured rat carotid artery. J Vasc Surg 1994; 20: 209-217.
26. Hasenstab D, Forough R, Clowes AW: Plasminogen activator inhibitor type 1 and tissue inhibitor of metalloproteinase-2 increase after arterial injury in rats. Circ Res 1997; 80: 490-496.
27. Kenagy RD, Vergel S, Mattsson E., Bendeck M, Reidy MA, Clowes AW: The role of plasminogen, plasminogen activators, and matrix metalloproteinases in primate arterial smooth muscle cell migration. Arterioscler Thromb Vasc Biol 1996; 16: 1373-1382.
28. Kenagy RD, Hart CE, Stetler-Stevenson WG, Clowes AW: Primate smooth muscle cell migration from aortic explants is mediated by endogenous platelet-derived growth factor and basic fibroblast growth factor acting through matrix metalloproteinases 2 and 9. Circulation 1997; 96: 3555-3560.
29. Aoyagi M, Yamamoto M, Azuma H, Nagashima G, Niimi Y, Tamaki M, Hirakawa K, Yamamoto K: Immunolocalization of matrix metalloproteinases in rabbit carotid arteries after balloon denudation. Histochem Cell Biol 1998; 109: 97-102.
30. Hojo Y, Ikeda U, Katsuki T, Mizuno O, Fujikawa H, Shimada K: Matrix metalloproteinase expression in the coronary circulation induced by coronary angioplasty. Atherosclerosis 2002; 161: 185-192.
31. Kalela A, Koivu TA, Sisto T, Kanervisto J, Hoyhtya M, Sillanaukee P, Lehtimaki T, Nikkari ST: Serum matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease. Scand J Clin Lab Invest 2002; 62: 337-342.
32. Lamblin N, Bauters C, Hermant X, Lablanche JM, Helbecque N, Amouyel P: Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease. J Am Coll Cardiol 2002; 40: 43-48.
33. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, Meyer J, Cambien F, Tiret L, AtheroGene Investigators: Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003; 107: 1579-1585.
34. Carmeliet P, Moons L, Stassen JM, De Mol M, Bouché A, van den Oord JJ, Kockx M, Collen D: Vascular wound healing and neointima formation induced by perivascular electric injury in mice. Am J Pathol 1997; 150: 761-776.
35. Lijnen HR, Lupu F, Moons L, Carmeliet P, Goulding D, Collen D: Temporal and topographic matrix metalloproteinase expression after vascular injury in mice. Thromb Haemost 1999; 81: 799-807.
36. Webb KE, Henney AM, Anglin S, Humphries SE, McEwan JR: Expression of matrix metalloproteinases and their inhibitor TIMP-1 in the rat carotid artery after balloon injury. Arterioscler Thromb Vasc Biol 1997; 17: 1837-1844.
37. Galis ZS, Johnson C, Godin D, Magid R, Shipley JM, Senior RM, Ivan E: Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res 2002; 91: 852-859.
38. Cho A, Reidy MA: Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ Res 2002; 91: 845-851.
39. Kuzuya M, Kanda S, Sasaki T, Tamaya-Mori N, Cheng XW, Itoh T, Itohara S, Iguchi A: Deficiency of gelatinase A suppresses smooth muscle cell invasion and development of experimental intimal hyperplasia. Circulation 2003; 108: 1375-1381.
40. Lijnen HR, Van Hoef B, Vanlinthout I, Verstreken M, Rio M-C, Collen D: Accelerated neointima formation after vascular injury in mice with stromelysin-3 (MMP-11) gene inactivation. Arterioscler Thromb Vasc Biol 1999; 19: 2863-2870.
41. Lijnen HR, Van Hoef B, Soloway P, Collen D: Tissue inhibitor type 1 of matrix metalloproteinases (TIMP-1) impairs arterial neointima formation after vascular injury in mice. Circ Res 1999; 85: 1186-1191.
42. Lovdahl C, Thyberg J, Cercek B, Blomgren K, Dimayuga P, Kallin B, Hultgardh-Nilsson A: Antisense oligonucleotides to stromelysin mRNA inhibit injury-induced proliferation of arterial smooth muscle cells. Histol Histopathol 1999; 14: 1101-1112.
43. Peterson M, Porter KE, Loftus IM, Thompson MM, London NJ: Marimastat inhibits neointimal thickening in a model of human arterial intimal hyperplasia. Eur J Vasc Endovasc Surg 2000; 19: 461-467.
44. de Smet BJ, de Kleijn D, Hanemaaijer R, Verheijen JH, Robertus L, van Der Helm YJ, Borst C, Post MJ: Metalloproteinase inhibition reduces constrictive arterial remodeling after balloon angioplasty: a study in the atherosclerotic Yucatan micropig. Circulation 2000; 101: 2962-2967.
45. Li C, Cantor WJ, Nili N, Robinson R, Fenkell L, Tran YL, Whittingham HA, Tsui W, Cheema AN, Sparkes JD, Pritzker K, Levy DE, Strauss BH: Arterial repair after stening and the effects of GM60001, a matrix metalloproteinase inhibitor. J Am Coll Cardiol 2002; 39: 1852-1858.
46. Zempo N, Koyama N, Kenagy RD, Lea HJ, Clowes AW: Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler Thromb Vase Biol 1996; 16: 28-33.
47. Forough R, Koyama N, Hasenstab D, Lea H, Clowes M, Nikkari ST, Clowes AW: Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. Circ Res 1996; 79: 812-820.
48. Furman C, Luo Z, Walsh K, Duverger N, Copin C, Fruchart JC, Rouis M: Systemic tissue inhibitor of metalloproteinase-1 gene delivery reduces neointimal hyperplasia in balloon-injured rat carotid artery. FEBS Lett 2002; 531: 122-126.
49. Turunen MP, Puhakka HL, Koponen JK, Hiltunen MO, Rutanen J, Leppanen O, Turunen AM, Narvanen A, Newby AC, Baker AH, Yla-Herttuala S: Peptide-retargeted adenovirus encoding a tissue inhibitor of metalloproteinase-1 decreases restenosis after intravascular gene transfer. Mol Ther 2002; 6: 306-312.
50. George SJ, Johnson JL, Angelini GD, Newby AC, Baker AH: Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. Hum Gene Ther 1998; 9: 867-877.
51. Lamfers MLM, Grimbergen JM, Aalders MC, Havenga MJ, de Vries MR, Huisman LGM, van Hinsbergh VWM, Quax PHA: Gene transfer of the urokinase-type plasminogen activator receptor-targeted matrix metalloproteinase inhibitor TIMP-1. ATF suppresses neointima formation more efficiently than tissue inhibitor of metalloproteinase-1. Circ Res 2002; 91: 945-952.
52. Schneiderman J, Bordin GM, Engelberg I, Adar R, Seiffert D, Thinnes T, Bernstein EF, Dilley RB, Loskutoff DJ: Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall. A possible mechanism for aneurysm expansion. J Clin Invest 1995; 96: 639-645.
53. Lupu F, Heim DA, Bachmann F, Hurni M, Kakkar VV, Kruithof EK: Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1995; 15: 1444-1455.
54. Henney AM, Wakeley PR, Davies MJ, Foster K, Hembry R, Murphy G, Humphries S: Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci USA 1991; 88: 8154-8158.
55. Galis SZ, Muszynski M, Sukhova GK, Simon-Morrisey E, Libby P: Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann NY Acad Sci 1995; 748: 501-507.
56. Schonbeck J, Mach F, Sukhova GK, Atkinson E, Levesque E, Herman M, Graber P, Basset P, Libby P: Expression of stromelysin-3 in atherosclerotic lesions: regulation via CD40-CD40 ligand signaling in vitro and in vivo. J Exp Med 1999; 189: 843-853.
57. Rajavashisth TB, Xu XP, Jovinge S, Meisel S, Xu XO, Chai NN, Fischbein MC, Kaul S, Cercek B, Sharifi B, Shah PK: Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators. Circulation 1999; 99: 3103-3109.
58. Hong BK, Kwon HM, Lee BK, Kim D, Kim IJ, Kang SM, Jang Y, Cho SH, Kim HK, Jang BC, Cho SY, Kim HS, Kim MS, Kwon HC, Lee N: Coexpression of cycloxygenase-2 and matrix metalloproteinases in human aortic atherosclerotic lesions. Yonsei Med J 2000; 41: 82-88.
59. Uzui H, Harpf A, Liu M, Doherty TM, Shukla A, Chai NN, Tripathi PV, Jovinge S, Wilkin DJ, Asotra K, Shall PK, Rajavashisth TB: Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque: role of activated macrophages and inflammatory cytokines. Circulation 2002; 106: 3024-3030.
60. Xu XP, Meisel SR, Ong JM, Kaul S, Cercek B, Rajavashisth TB, Sharifi B, Shah PK: Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation 1999; 99: 993-998.
61. Moreau M, Brocheriou I, Petit L, Ninio E, Chapman MJ, Rouis M: Interleukin-8 mediates downregulation of tissue inhibitor of metalloproteinase-1 expression in cholesterol-loaded human macrophages: relevance to stability of atherosclerotic plaque. Circulation 1999; 99: 420-426.
62. Fabunmi RP, Sukhova GK, Sugiyama S, Libby P: Expression of tissue inhibitor of metalloproteinases-3 in human atheroma and regulation in lesion-associated cells: a potential protective mechanism in plaque stability. Circ Res 1998; 83: 270-278.
63. Orbe J, Fernandez L, Rodriguez JA, Rabago G, Belzunce M, Monasterio A, Roncal C, Paramo JA: Different expression of MMPs/TIMP-1 in human atherosclerotic lesions. Relation to plaque features and vascular bed. Atherosclerosis 2003; 170: 269-276.
64. Saito S, Zempo N, Yamashita A, Takenaka H, Fujioka K, Esato K: Matrix metalloproteinase expressions in arteriosclerotic aneurysmal disease. Vasc Endovascular Surg 2002; 36: 1-7.
65. Beaudeux JL, Giral P, Bruckert E, Bernard M, Foglietti MJ, Chapman MJ: Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 as potential markers of carotid atherosclerosis in infraclinical hyperlipidemia. Atherosclerosis 2003; 169: 139-146.
66. Ferroni P, Basili S, Martini F, Cardarello CM, Ceci F, Di Franco M, Bertazzoni G, Gazzaniga PP, Alessandri C: Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation. J Investig Med 2003; 51: 295-300.
67. Jormsjo S, Wuttge DM, Sirsjo A, Whatling C, Hamsten A, Stemme S, Eriksson P: Differential expression of cysteine and aspartic proteases during progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 2002; 161: 939-945.
68. Dollery CM, Owen CA, Sukhova GK, Krettek A, Shapiro SD, Libby P: Neutrophil elastase in human atherosclerotic plaques: production by macrophages. Circulation 2003; 107: 2829-2836.
69. Shi W, Brown MD, Wang X, Wong J, Kallmes DF, Matsumoto AH, Helm GA, Drake TA, Lusis AJ: Genetic backgrounds but not sizes of atherosclerotic lesions determine medial destruction in the aortic root of apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2003; 23: 1901-1906.
70. Silence J, Lupu F, Collen D, Lijnen HR: Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol 2001; 21: 1140-1145.
71. Luttun A, Lutgens E, Manderveld A, Maris K, Collen D, Carmeliet P, Moons L: Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation 2004; 109: 1408-1414.
72. Silence J, Collen D, Lijnen HR: Reduced atherosclerotic plaque but enhanced aneurysm formation in mice with inactivation of the tissue inhibitor of metalloproteinase-1 (TLMP-1) gene. Circ Res 2002; 90: 897-903.
73. Lemaitre V, Soloway PD, D'Armiento J: Increased medial degradation with pseudo-aneurysm formation in apolipoprotein E-knockout mice deficient in tissue inhibitor of metalloproteinases-1. Circulation 2003; 107: 333-338.
74. Rouis M, Adamy C, Duverger N, Lesnik P, Horellou P, Moreau M, Emmanuel F, Caillaud JM, Laplaud PM, Dachet C, Chapman MJ: Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E-deficient mice. Circulation 1999; 100: 533-540.
75. Allaire E, Forough R, Clowes M, Starcher B, Clowes AW: Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model. J Clin Invest 1998; 102: 1413-1420.
76. Carmeliet P, Moons L, Lijnen HR, Baes M, Lemaitre V, Tipping P, Drew A, Eeckhout Y, Shapiro S, Lupu F, Collen D: Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 1997; 17: 439-444.
77. Bocan TM, Krause BR, Rosebury WS, Mueller SB, Lu X, Dagle C, et al: The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 2000; 20: 70-79.
78. Cherr GS, Motew SJ, Travis JA, Fingerle J, Fisher L, Brandl M, et al: Metalloproteinase inhibition and the response to angioplasty and stenting in atherosclerotic primates. Arterioscler Thromb Vasc Biol 2002; 22: 161-166.
79. Orbe J, Rodriguez JA, Arias R, Belzunce M, Nespereira B, Perez-Ilzarbe M, Roncal C, Paramo JA: Antioxidant vitamins increase the collagen content and reduce MMP-1 in a porcine model of atherosclerosis: implications for plaque stablization. Atherosclerosis 2003; 167: 45-53.
80. Axisa B, Loftus IM, Naylor AR, Goodall S, Jones L, Bell PR, Thompson MM: Prospective, randomized, double-blind trial investigating the effect of doxycycline on matrix metalloproteinase expression within atherosclerotic carotid plaques. Stroke 2002; 33: 2858-2864.
81. George SJ: Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis. Exp Opin Invest Drugs 2000; 9: 993-1007.
82. Watanabe N, Ikeda U: Matrix metalloproteinases and atherosclerosis. Curr Atheroscler Rep 2004; 6: 112-120.
83. Beaudeux JL, Giral P, Bruckert E, Foglietti MJ, Chapman MJ: Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin Chem Lab Med 2004; 42: 121-131.